Pasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock Up
Pasithea Therapeutics (KTTA) reported tumor shrinkage in all 15 patients treated with PAS-004 in a Phase 1/1b NF1 trial, with a median 41% reduction in skin tumors. Two patients showed partial responses in nerve-associated tumors. The drug was well-tolerated. KTTA plans a Phase 2 study and stock rose 11.41% in pre-market trading.
How this was made
The 30-second read
Why it matters
The disclosed efficacy signals could trigger short‑term buying interest and raise the company's profile among rare‑disease investors.
Market read
First disclosure of positive trial data for a micro‑cap biotech, offering a potential catalyst for price movement.
What to watch
Potential regulatory hurdles and need for larger, controlled Phase 2 data before meaningful valuation shift.
Background
Pasithea Therapeutics (KTTA) presented Phase 1/1b data at the European Neurofibromatosis Conference, showing tumor size reductions in all evaluable NF1 patients.
Ticker impact
Pasithea Therapeutics reported positive Phase 1/1b tumor‑shrinkage data for PAS‑004 in NF1 patients, the first disclosure of these results.
likely upward pressure as traders price in the promising efficacy signals.
First report of meaningful tumor reductions and partial responses in a rare disease, a material catalyst for a micro‑cap biotech.
Market effects
May boost interest in NF1 and rare‑disease biotech pipelines.
Limited to US biotech investors.
Low global impact beyond niche biotech community.
Counterpoint
Data are early‑stage; efficacy may not translate to later trials, risk of failure remains high.
Key entities
- companyPasithea Therapeutics Corp.
Biotech developing PAS‑004 for NF1-associated tumors.
- drugPAS‑004
Experimental therapy targeting neurofibromatosis type 1.
